Deciphering the function of factors involved in spinal cord neuroinflammation and tissue plasticity associated with neuropathic pain Pathological pain is characterized by extensive modification of the systems involved in pain signal transmission and modulation at the spinal level (primary sensory neurons and the spinal cord) and probably in the brain. Chronic pain, particularly of neuropathic origin, may also lead to tissue remodeling (plasticity). This may include, for instance, loss of spinal interneurons, abnormal rearrangement of central afferents of primary sensory neurons and glial cell activation and proliferation. These long-lasting modifications are mediated by, or associated with, changes in the production of key molecules involved in nociceptive processing. Genebased techniques allow local or even cell-type-specific interventions to be used to correct the abnormal production of some of these proteins, modulate the activity of signal transduction pathways or overproduce various therapeutic secreted proteins. In fact, with these approaches, it may be possible to not 'only' relieve established ongoing pain but to reverse the pathological situation underlying chronic pain.
The importance of changes in glial cell status (so-called activation) in the spinal cord, [1] [2] [3] [4] dorsal root ganglia (DRG) 5 and even brain structures 6, 7 in generating and also probably maintaining neuropathic pain is now well established. Indeed, activation of spinal cord glia has been associated with almost all animal models of neuropathic pain (see L Watkins section in this volume). Activated glia (microglia and astrocytes) produces and releases several molecules (gliotransmitters) that may act directly on sensory neurons (modifying the excitability of both first-and second-order neurons) and/or glial cells themselves (maintaining their high level of activity). Although alteration of glial cell function clearly participates in the development of long-term neuroinflammation in the spinal cord, thus having an important function in pathological pain, the precise mechanisms involved are still a matter of debate. Pharmacological studies have implicated numerous receptors, transduction pathways and secreted mediators in central sensitization in the spinal cord following peripheral nerve injury. However, tools need to be developed to determine the relative input of glia and neurons. Indeed, both neurons and glia express several receptors potentially involved in glia activation (for example, receptors for certain cytokines, chemokines, glutamate, ATP, substance P) and in both cell types several signal transduction pathways are also activated following peripheral nerve injury (for example, p38 MAP kinase, 8 JNK 9 and ERK 10 ). The actual source of pro-inflammatory and algogenic mediators present in the spinal cord after peripheral nerve lesion is difficult to determine, given that most of them (glutamate, cytokine IL-6, chemokine CCL2, ATP, nitric oxide, prostaglandins and so on) may be synthesized in and released from both neurons and glial cells. Thus, separate in vivo studies of glia or neurons, using different models of chronic pain and distinguishing between peripheral (especially those involving primary sensory neurons) and central mechanisms, will be needed to determine the precise nature and chronological order of the events leading to the development and maintenance of pain. Classical pharmacological approaches are not sufficient to fulfill such criteria. Indeed, the selectivity of some molecules is only relative, local delivery is problematic due to the substantial diffusion of agents, intrathecal delivery of various compounds frequently leads to their massive accumulation in pia mater and in DRG, 9, 11, 12 prolonged delivery of drugs is only possible with minipump systems, leading to a broad and diffuse action of the drug, and cellselective treatment is almost impossible.
Molecular mechanisms involved in the activation of spinal cord glia and/or the induction of glia-derived deleterious products undoubtedly represent therapeutic targets of potential interest. It may be possible to use local and cell-type-selective interventions to modulate some of these cellular mechanisms in the spinal cord glia and to determine the importance of these mechanisms in the modification of glial cell function, production of algogenic mediators and, ultimately, in chronic pain. This approach would require a direct intraparenchymal injection of vectors rather than intrathecal administration, which tends to the predominant transduction of meningeal cells or DRG sensory neurons and only very modest transduction of spinal cord tissue. [13] [14] [15] Additionally, central nervous system (CNS) intraparenchymal injection of vector limits the systemic immune response, thus inducing only a negligible inflammatory response. 16 Lentiviral vectors as a potential tool for targeting spinal cord glia Lentiviral (LV) vectors appear to be the best candidates for targeting spinal cord glia. Indeed, primo-infection of vectors with entire viral coding regions deleted from the viral genome, administered into the CNS, induces only negligible, asymptomatic inflammation 17, 18 with no detectable systemic immune response or immune clearance of vectors. 19 Vectors are constructed from viral particle proteins and replication enzymes provided in trans from distinct expression plasmids. In the same way, envelope glycoproteins (of non-LV origin) are generated from different expression cassettes, allowing vector 'pseudotyping' with various viral envelope glycoproteins that can be used to target particular cells. 20 For instance, LV pseudotyped with rabies-G protein may be transported retrogradely and allow the targeting of distant neurons. 21 However, the possible retrograde transport depends on the particular nerve pathway examined. Vesicular stomatitis virus (VSV)-G-and Mokola virus-pseudotyped LV vectors can target rat olfactory neuron cell bodies following intranasal application, whereas their intramuscular delivery does not lead to transportation to the ventral spinal cord motoneurons. 18, 22 The pseudotyping of LV with envelope proteins from Mokola or amphotropic murine leukemia virus confers a potent capacity to transfect human neuroblastoma cell lines, 23 and Ross River virus pseudotypes seem relatively efficient for glia transfection. 24 Through the integration of the LV genome into host genomic DNA, LV-derived vectors can be used for longterm transgene production. Although this may be of particular interest for some gene therapy protocols (limiting the need for repeated administration and the potential development of subsequent immune reaction), the risk of insertional mutagenesis may also limit their use in clinical applications. Recently, nonintegrative LV vectors containing a defective integrase and allowing the formation of circular episomal genomes in the nucleus of transduced cells were developed. 25, 26 These vectors still drive efficient and sustained transgene expression in vivo, particularly in brain tissue, but have substantially reduced risk of insertional mutagenesis; this type of vector may therefore be of real interest for therapeutic applications.
LVs used for vector construction are mostly derived from primate (human and simian) or nonprimate (equine and feline) immunodeficiency viruses. 27 Human immunodeficiency virus (HIV)-1-derived vectors pseudotyped with VSV envelope protein and carrying the cytomegalovirus (CMV) promoter were originally reported to transduce mostly neuronal cells in brain structures. 17, 28 It has since been established that the VSV-G envelope protein confers a fairly broad spectrum of tissue tropism and is thus widely used for LV vector pseudotyping. 29 A substantial proportion of cerebral astrocytes may be also infected using this vector type. 20, 30, 31 Published data suggest that LV transduction efficacy differs between animal species (mouse versus rat) and between distinct cerebral structures. Very little data are available on the tropism of these vectors in vivo in the spinal cord.
In initial experiments, we compared LV vectors pseudotyped with envelope protein from VSV-G or Mokola virus and producing the EGFP reporter protein under either the CMV or phosphoglycerate kinase promoter. We found that VSV-G pseudotyped HIV-derived vectors driving transgene expression under the control of the CMV promoter (LV-EGFP) could preferentially target spinal cord glial cells. We showed that these vectors have a particularly high capacity to target and transduce glial cells both in vitro and in vivo. The infection (B15 ng of p24 (LV envelope protein used for vector titration with enzyme-linked immunosorbent assay)) of rat spinal cord neurons/glia in vitro, in primary cocultures containing increasing proportion of neurons (up to 90%), resulted in strong transgene expression in a large proportion of astrocytes, with relatively low levels of enhanced green fluorescent protein (EGFP) detected in only a few neurons (Figure 1) . Similarly, direct microinjection of vectors into the rat spinal cord in vivo resulted in a preferential transduction of glial cells. The majority (B91%) of EGFPproducing cells were astrocytes and microglia; less than 9% of cells were identified as neurons (Figure 2) . Additionally, LV-mediated transgene expression was consistently weaker in these neurons than in glia. We did not determine the precise number of infected astrocytes and microglial cells, but their proportion was estimated to be about 60 and 40%, respectively. These data are consistent with studies using HIV-based vectors similar to the vectors used in our studies. These studies showed that administration of these vectors in the spinal cord transduced astrocytes predominantly, and microglial cells and neurons to a lesser extent. 32, 33 Glial cells are highly reactive to microbial or physical attack; thus, we tried to establish a minimally invasive approach for intraparenchymal microdelivery of LV
and vector delivery (volume, rate, concentration) were finely tuned to avoid local inflammation and to restrict diffusion (unilateral) of the vector into the dorsal spinal cord. Instead of a hemilaminectomy (highly invasive surgery that frequently induces extensive inflammatory reaction), access to the dorsal lumbar enlargement was opened by a B1 mm hole carefully drilled unilaterally through the vertebra. Viral suspension (2 ml; 60-80 ng of p24) was then microinjected using a heat-pulled glass capillary needle (B80 mm external diameter) that, in contrast to steel needles, induced only very limited glial scarring. This single intraparenchymal injection into the dorsal horn of the spinal cord allowed the viral vector to spread through B3-4 mm of the rostrocaudal axis, covering a reasonable area of the lumbar enlargement. However, diffusion of the vector was tightly restricted to the ipsilateral, injected dorsal horn. Surgery, the microinjection procedure and LV infection induced a negligible inflammatory response in the spinal cord (monitored by measurement of the production of highly inducible markers of inflammation, using quantitative reverse transcription-PCR) with no change in nociceptive threshold or locomotor activity in control animals. 34 Overall, these findings demonstrate that the LV vectors and method of administration used in these studies allow the local and cell-selective modulation of potentially relevant systems in spinal cord glial cells.
The use of LV vectors for the control of intracellular signal transduction pathways in glial cells
The nuclear factor kB (NF-kB) transduction pathway may be particularly relevant in the modification of glial function associated with neuropathic pain. Indeed, this transcription factor regulates a broad panel of target genes, including those encoding numerous pro-inflammatory cytokines and key proteins involved in inflammatory and immune responses. [35] [36] [37] We and others 38 have demonstrated its rapid activation in spinal cord glial cells following peripheral nerve injury. The NF-kB transduction pathway has also been implicated in pain hypersensitivity. 39, 40 NF-kB is a pleiotropic factor involved in CNS homeostasis and having an important antiapoptotic function in neurons (apoptosis of certain types of spinal cord neurons being clearly associated with neuropathic pain 41 ). Experimental procedures must therefore keep the NF-kB pathway intact in neurons, at the same time selectively reducing its activity in glial cells of the spinal cord. In resting conditions, NF-kB is sequestrated in its inactive form in the cytoplasm by its interaction with an inhibitory IkB protein. Various stimuli may activate specific kinases, initiating IkB degradation through phosphorylation of this protein.
IkB degradation unmasks the NF-kB nuclear localization signal allowing its translocation into the nucleus, where NF-kB induces the transcription of target genes. We generated VSV-pseudotyped LV vector expressing a mutated, degradation-resistant (super-repressor) form of the inhibitory protein IkB (LV-srIkB). In vitro, in primary cultures of spinal cord glial cells, these vectors strongly inhibited the lipopolysaccharides (LPS)-activated NF-kB pathway. Indeed, in contrast to LPSstimulated control cells displaying marked accumulation of NF-kB in cell nuclei, the nuclear translocation of NF-kB was completely abolished in glial cells infected with LV-srIkB (Figure 3 ). Functional blockade of the NF-kB pathway in LV-srIkB-infected glial cells was further demonstrated by the prevention of LPS-induced expression of several inflammatory markers such as IL-6, IL-1b or TNF-a.
In vivo intraspinal administration of LV-srIkB (2 ml, that is, B60 ng of p24) led to the robust and longterm (up to 6 months, the maximal time course in our experiments) production of srIkB in cells. Most of these cells were identified as astrocytes or microglia (double labeled for glial fibrillary acidic protein (GFAP) or Ox42 markers). This local and glia-specific overproduction of 
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IkB inhibitory protein had neither acute nor long-term behavioral consequences (basal thermal or mechanical pain sensitivity, locomotor activity) in control healthy rats. We demonstrated a rapid and prolonged activation of NF-kB (ipsilateral to the lesioned nerve) in a classical model of neuropathic pain evoked by chronic constriction injury (CCI 42 ) of the sciatic nerve. This suggests a function for NF-kB signaling early in the trans-synaptic spinal response to peripheral nerve injury. CCI-induced neuropathic pain is also associated with the upregulation of several proinflammatory cytokines 43, 44 and, as we demonstrated, a delayed induction of iNOS. Preemptive unilateral administration of LV-srIkB into the dorsal spinal cord of the lumbar enlargement (projection site of central afferents of injured nerves) led to a complete blockade of NF-kB nuclear translocation (that is, activation of NF-kB signaling) in CCI animals. This transgenemediated NF-kB blockade had a direct functional effect on the abnormal production of inflammation-and painrelated molecules in the spinal cord of CCI rats. Indeed, LV-srIkB almost completely prevented the CCI-associated increase of IL-6 and iNOS mRNA levels. This local inhibition of NF-kB activity in glial cells of the (unilateral) lumbar spinal cord attenuated the thermal hyperalgesia and mechanical allodynia that develop after CCI of the sciatic nerve. 45 Our data thus demonstrate that VSV-pseudotyped HIV-derived vectors can mediate local gene transfer Figure 2 In vivo, lentiviral enhanced green fluorescent protein (LV-EGFP) transduces preferentially astrocytes and microglial cells in the dorsal horn of the rat spinal cord. A majority of EGFP fluorescent cells (in green) were colabeled with glial fibrillary acidic protein (GFAP) (astrocytic marker, a) or with OX42 (microglial marker, b). By contrast, less than 9% of cells endowed with EGFP staining were colabeled with NeuN (neuronal marker, c). Moreover, when observed, EGFP fluorescence in neurons was consistently weaker than that present in nonneuronal cells (white arrow). Scale bar ¼ 50 mm.
into the spinal cord parenchyma, displaying a strong preference for glia. We also showed that this approach can be used to modulate, in a highly specific manner, glial cell signal transduction; this targeted intervention may thus be useful to determine the importance of molecular targets in pathological mechanisms and, of course, their potential therapeutic interest.
The use of LV vectors in the prospect for new therapeutic targets associated with spinal cord glia
The use of LV vectors to drive the production of an intracellular inhibitory protein targeting a signal transduction pathway (transcription factor) in the study 47 )). Such expression systems are of particular interest for the use of vectors in vivo. LV vectors may also be useful for the generation of small hairpin RNA (silencing of gene expression by RNA interference). Although the cell specificity of LV vectors bearing particular promoters to produce such RNA is still subject to investigation, their functional potency was recently demonstrated in the nervous system. 48, 49 Another possible application of LV is the vector-mediated expression of the Cre recombinase gene for conditional genomic modifications. Region-selective administration of such vectors in knockin mice with DNA sequences flanked by Cre-loxP may lead to the activation or disruption of targeted genes in a time-and cell-population-specific manner. 50 Several examples have been recently demonstrated, suggesting that region-and cell-type-selective intervention may be particularly helpful in understanding the function and real importance of particular systems in pathological pain. For instance, the chemokine fractalkine and its receptor CX 3 CR1 have been implicated in pain but their precise function remains elusive. CX 3 CR1 is constitutively expressed in spinal cord microglia and upregulated following the induction of neuropathic pain by peripheral nerve injury in rats. Intrathecal administration of anti-CX 3 CR1 neutralizing antibodies attenuates neuropathic pain symptoms. 51, 52 However, peripheral nerve injury in the mouse is associated with CX 3 CR1 upregulation in macrophages in the DRG and near the site of injury of the sciatic nerve, and intraneural injection of fractalkine in the sciatic nerve delays allodynia development in the spared nerve injury (SNI) model of neuropathic pain. Moreover, CX 3 CR1 knockout mice display increased allodynic behavior after SNI. These data thus suggest that fractalkine exerts a potent antiallodynic effect mediated by CX 3 CR1, at least in mice. 53 The region-and cell-selective modulation of CX 3 CR1 expression levels could thus be a possible approach to clarify the effect of fractalkine on the generation of pain.
As mentioned above, various signaling pathways (p38 MAP kinase, JNK, ERK) are sequentially activated in glia and neurons (or neurons and glia) following changes induced in peripheral nerves leading to the development of neuropathic pain. Pharmacological intervention, however, does not allow the relative importance of the activation of pathways in pain processing in either cell type to be determined. Similarly, such methods do not reveal whether blockade of these pathways in one cell type would have any effect on the further activation of these pathways in subsequent cell types.
The examples highlighted above thus demonstrate that LV vectors may be exploited for many applications, not only in therapeutic trials but also as tools in the search for new potential therapeutic targets and their in vivo validation in pertinent models of pathological pain.
